A Phase I, Randomized, Single and Multiple Ascending Dose, Placebo-Controlled, Double-Blind Study to Determine the Safety, Tolerability, and Pharmacokinetics of GDC-0310 in Healthy Volunteers
Latest Information Update: 17 Sep 2021
At a glance
- Drugs GDC 0310 (Primary)
- Indications Pain
- Focus Adverse reactions
- Sponsors Genentech
Most Recent Events
- 28 Jun 2016 Status changed from recruiting to completed.
- 26 Oct 2015 New trial record